methylprednisolone sodium succinate

The immune mechanism of its occurrence is still unclear and needs to be further studied. Traditional glucocorticoid is still the first-line drug, but the new targeted drug Efgartigimod has less adverse reactions and faster onset of action, which may become a good choice, but needs to be verified by a larger sample.

P3, N=3208, Completed, Children's Hospital of Fudan University | Active, not recruiting --> Completed

Immediate discontinuation of almonertinib combined with intravenous methylprednisolone resulted in significant clinical and radiological improvement within 7 days. This case highlights two important clinical implications: (1) almonertinib-associated ILD can rapidly progress to a life-threatening condition and (2) occupational inhalational exposures (e.g., dust and smoking) have been directly and indirectly implicated as potential risk factors for EGFR-TKI-induced pulmonary toxicity in prior studies and may have contributed to the outcome in this case. Clinicians should maintain heightened vigilance for respiratory complications during almonertinib therapy, particularly in patients with preexisting pulmonary risk factors.

P4, N=220, Recruiting, Sunnybrook Health Sciences Centre | Not yet recruiting --> Recruiting

High-dose corticosteroid therapy (three courses of intravenous methylprednisolone pulse) resulted in only partial clinical improvement...By day 82 of hospitalization, the patient was able to ambulate independently. This case suggests that in overlapping autoimmune syndromes, early escalation to PE should be considered when conventional steroid therapy is insufficient.

Etanercept might be contemplated for "off-label" use in gout patients who do not respond to standard therapy or glucocorticoid therapy, encounter severe side-effects and contraindications.

P2, N=150, Active, not recruiting, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Not yet recruiting --> Active, not recruiting

A 58-year-old man with KRAS-G12C-mutated stage IVB lung adenocarcinoma initiated first-line treatment with carboplatin + pemetrexed + pembrolizumab...Intravenous methylprednisolone led to rapid defervescence and biochemical improvement...Thereafter, he initiated adagrasib, achieving a durable partial response. This case illustrates discordance between metabolic quiescence and later structural damage in immune checkpoint inhibitor-associated aortitis. This supports long-term structural surveillance, as 18F-FDG PET/CT normalization does not guarantee structural safety.

P1/2, N=10, Terminated, Masonic Cancer Center, University of Minnesota | N=55 --> 10 | Trial completion date: Sep 2028 --> Feb 2026 | Suspended --> Terminated | Trial primary completion date: Sep 2026 --> Feb 2026; Sponsor terminated financial support

P=N/A, N=81, Completed, Xijing Hospital of Digestive Diseases

P4, N=200, Recruiting, Chinese PLA General Hospital | Not yet recruiting --> Recruiting | Trial completion date: Jun 2026 --> Jun 2029 | Trial primary completion date: Jun 2026 --> Jun 2027

P1/2, N=15, Recruiting, Prevail Therapeutics | Active, not recruiting --> Recruiting